Xenetic first patient dosing in a clinical trial involving its DNase I platform in combination with FOLFIRINOX through a collaboration with PeriNess Ltd. This development highlights progress in the company's immuno-oncology efforts, particularly for pancreatic cancer treatments, building on recent expansions in partnerships like with Scripps for DNase-CAR T therapies. Social media buzz amplified the news, noting explosive pre-market gains up to 403% and strong retail interest in the micro-cap biotech's thin float, which often leads to high volatility. As a result, this positions the firm closer to Phase 1 trials, potentially attracting further investor attention amid a niche focus on rare disease R&D that can drive significant upside in the sector.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.